Evidence map›Paper›PMID 38188290›Full record

ArticleFrontiers in oncology2023

27-hydroxycholesterol and DNA damage repair: implication in prostate cancer.

Gloria Cecilia Galvan, Nadine A Friedrich, Sanjay Das, James P Daniels, Sara Pollan, Shweta Dambal, Ryusuke Suzuki, Sergio E Sanders, Sungyong You, Hisashi Tanaka and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Androgens are a Key Factor Affecting Immune Related Diseases.The world journal of men's health · 2026
    Review
  2. Review
  3. 27-Hydroxycholesterol in cancer development and drug resistance.Journal of enzyme inhibition and medicinal chemistry · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Gloria Cecilia Galvan *Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Nadine A Friedrich *Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Sanjay DasDepartment of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
James P DanielsDepartment of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Sara PollanDepartment of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Shweta DambalDepartment of Pathology, Duke University School of Medicine, Durham, NC, United States.
Ryusuke SuzukiDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Sergio E SandersDepartment of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Sungyong YouDepartment of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Hisashi TanakaDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Yeon-Joo LeeDepartment of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Wei YuanCancer Biomarkers Team, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.
Johann S de BonoCancer Biomarkers Team, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.
Irina VasilevskayaDepartment of Cancer Biology at Thomas Jefferson University, Philadelphia, PA, United States.
Karen E KnudsenDepartment of Cancer Biology at Thomas Jefferson University, Philadelphia, PA, United States.
Michael R FreemanDepartment of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Stephen J FreedlandDepartment of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Cedars-Sinai Medical Center · USThomas Jefferson University · USDuke University · USDurham VA Health Care System · USInstitute of Cancer Research · GBLondon Cancer · GBVeterans Health Administration · US

Funding

Training CoreTL1DK132768 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2021 to 2026
$3.4M
Mechanisms of gene amplification in human cancersR01CA149385 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI TANAKA, HISASHI · 2010 to 2022
$3.4M
Network CoreU2CDK129496 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Stephen Jay Freedland, TOMAS GANZ · 2021 to 2026
$2.9M
Mechanisms of Prostate Cancer MetastasisR01CA271750 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FREEMAN, MICHAEL R., GARRAWAY, ISLA PEARL · 2021 to 2025
$2.2M
Patient-Centered Outcomes Research Training in Urologic and Gynecologic Cancers (PCORT UroGynCan)T32CA251072 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Beth Y. Karlan, MARK S. LITWIN · 2020 to 2026
$2.1M
A multidisciplinary training program in prostate cancerT32CA240172 · NCI · CEDARS-SINAI MEDICAL CENTER · PI BHOWMICK, NEIL A., FREEDLAND, STEPHEN JAY · 2019 to 2023
$988k
Medical Research Council MR/W018217/1NCI NIH HHS R01 CA149385NCI NIH HHS R01 CA271750NCI NIH HHS T32 CA240172NCI NIH HHS T32 CA251072NIDDK NIH HHS TL1 DK132768NIDDK NIH HHS U2C DK129496
6 · The paper itself

Abstract

Introduction: We previously reported that cholesterol homeostasis in prostate cancer (PC) is regulated by 27-hydroxycholesterol (27HC) and that CYP27A1, the enzyme that converts cholesterol to 27HC, is frequently lost in PCs. We observed that restoring the CYP27A1/27HC axis inhibited PC growth. In this study, we investigated the mechanism of 27HC-mediated anti-PC effects. Methods: We employed in vitro models and human transcriptomics data to investigate 27HC mechanism of action in PC. LNCaP (AR+) and DU145 (AR-) cells were treated with 27HC or vehicle. Transcriptome profiling was performed using the Affymetrix GeneChip™ microarray system. Differential expression was determined, and gene set enrichment analysis was done using the GSEA software with hallmark gene sets from MSigDB. Key changes were validated at mRNA and protein levels. Human PC transcriptomes from six datasets were analyzed to determine the correlation between CYP27A1 and DNA repair gene expression signatures. DNA damage was assessed via comet assays. Results: Transcriptome analysis revealed 27HC treatment downregulated Hallmark pathways related to DNA damage repair, decreased expression of FEN1 and RAD51, and induced "BRCAness" by downregulating genes involved in homologous recombination regulation in LNCaP cells. Consistently, we found a correlation between higher CYP27A1 expression (i.e., higher intracellular 27HC) and decreased expression of DNA repair gene signatures in castration-sensitive PC (CSPC) in human PC datasets. However, such correlation was less clear in metastatic castration-resistant PC (mCRPC). 27HC increased expression of DNA damage repair markers in PC cells, notably in AR+ cells, but no consistent effects in AR- cells and decreased expression in non-neoplastic prostate epithelial cells. While testing the clinical implications of this, we noted that 27HC treatment increased DNA damage in LNCaP cells via comet assays. Effects were reversible by adding back cholesterol, but not androgens. Finally, in combination with olaparib, a PARP inhibitor, we showed additive DNA damage effects. Discussion: These results suggest 27HC induces "BRCAness", a functional state thought to increase sensitivity to PARP inhibitors, and leads to increased DNA damage, especially in CSPC. Given the emerging appreciation that defective DNA damage repair can drive PC growth, future studies are needed to test whether 27HC creates a synthetic lethality to PARP inhibitors and DNA damaging agents in CSPC.

Indexed as

27-hydroxycholesterol (27HC)CYP27A1DU145 (prostate) cancer cell linehydroxycholesterolLNCaP (prostate cancer cell)prostate cancer

Identifiers

PMID38188290
PMCPMC10771304
OpenAlexW4390056198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.